Hye Won Lee1,2,3, Beom Kyung Kim1,2,3, Seung Up Kim1,2,3, Jun Yong Park1,2,3, Do Young Kim1,2,3, Sang Hoon Ahn1,2,3,4, Kwang Joon Kim1,5,6, Kwang-Hyub Han7,8,9,10. 1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 2. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea. 3. Yonsei Liver Center, Seoul, South Korea. 4. Brain Korea 21 Project for Medical Science, Seoul, South Korea. 5. Division of Endocrinology, Yonsei University College of Medicine, Seoul, South Korea. 6. Severance Check-up Severance Hospital, Yonsei University Health System, Seoul, South Korea. 7. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. gihankhys@yuhs.ac. 8. Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, South Korea. gihankhys@yuhs.ac. 9. Yonsei Liver Center, Seoul, South Korea. gihankhys@yuhs.ac. 10. Brain Korea 21 Project for Medical Science, Seoul, South Korea. gihankhys@yuhs.ac.
Abstract
BACKGROUND/AIMS: Transient elastography (TE) can be used to assess the degree of liver fibrosis and steatosis. We investigated the prevalence and predictors of nonalcoholic fatty liver disease (NAFLD) with or without significant liver fibrosis in the general population. METHODS: A total of 3033 subjects without alcoholic or chronic viral liver diseases who underwent a medical health check-up including TE were recruited from April 2013 to August 2014. TE-defined NAFLD was defined as a controlled attenuation parameter of ≥250 dB/m, and significant liver fibrosis was defined as a liver stiffness (LS) value of ≥8 kPa. RESULTS: Overall, 1178 (42.9%) subjects had NAFLD. Subjects with NAFLD had significantly higher alanine aminotransferase (ALT) levels and a higher prevalence of parameters related to metabolic syndrome, such as high blood pressure, a high body mass index (BMI), glucose intolerance, and dyslipidemia than did subjects without NAFLD (all P < 0.05). Age, male gender, ALT level, serum albumin, BMI, diabetes, hypertriglyceridemia, and LS values independently showed positive associations with the presence of NAFLD (all P < 0.05). In addition, concomitant significant liver fibrosis was identified in 60 (5.1%) subjects with NAFLD, and its independent predictors were age [odds ratio (OR) 1.054], ALT level (OR 1.019), BMI (OR 1.217), and diabetes (OR 1.987) (all P < 0.05). CONCLUSIONS: We found that the prevalence of subjects with NAFLD was high (42.9%), and 5.1% of them had concomitant significant liver fibrosis. The risk factors found in this study can help identify which subjects with NAFLD are vulnerable to fibrosis progression.
BACKGROUND/AIMS: Transient elastography (TE) can be used to assess the degree of liver fibrosis and steatosis. We investigated the prevalence and predictors of nonalcoholic fatty liver disease (NAFLD) with or without significant liver fibrosis in the general population. METHODS: A total of 3033 subjects without alcoholic or chronic viral liver diseases who underwent a medical health check-up including TE were recruited from April 2013 to August 2014. TE-defined NAFLD was defined as a controlled attenuation parameter of ≥250 dB/m, and significant liver fibrosis was defined as a liver stiffness (LS) value of ≥8 kPa. RESULTS: Overall, 1178 (42.9%) subjects had NAFLD. Subjects with NAFLD had significantly higher alanine aminotransferase (ALT) levels and a higher prevalence of parameters related to metabolic syndrome, such as high blood pressure, a high body mass index (BMI), glucose intolerance, and dyslipidemia than did subjects without NAFLD (all P < 0.05). Age, male gender, ALT level, serum albumin, BMI, diabetes, hypertriglyceridemia, and LS values independently showed positive associations with the presence of NAFLD (all P < 0.05). In addition, concomitant significant liver fibrosis was identified in 60 (5.1%) subjects with NAFLD, and its independent predictors were age [odds ratio (OR) 1.054], ALT level (OR 1.019), BMI (OR 1.217), and diabetes (OR 1.987) (all P < 0.05). CONCLUSIONS: We found that the prevalence of subjects with NAFLD was high (42.9%), and 5.1% of them had concomitant significant liver fibrosis. The risk factors found in this study can help identify which subjects with NAFLD are vulnerable to fibrosis progression.
Authors: Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley Journal: Hepatology Date: 2010-09 Impact factor: 17.425
Authors: Hye Won Lee; Soo Young Park; Seung Up Kim; Jae Young Jang; Hana Park; Ja Kyung Kim; Chun Kyon Lee; Young Eun Chon; Kwang-Hyub Han Journal: PLoS One Date: 2016-06-10 Impact factor: 3.240
Authors: Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen Journal: Lancet Gastroenterol Hepatol Date: 2019-12-15
Authors: Jeong-Ju Yoo; Yang Jae Yoo; Woo Ram Moon; Seung Up Kim; Soung Won Jeong; Ha Na Park; Min Gyu Park; Jae Young Jang; Su Yeon Park; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han; Sang Gyune Kim; Young Seok Kim; Ji Hoon Kim; Jong Eun Yeon; Kwan Soo Byun Journal: Korean J Intern Med Date: 2019-11-08 Impact factor: 2.884
Authors: Gordon P Watt; Isela De La Cerda; Jen-Jung Pan; Michael B Fallon; Laura Beretta; Rohit Loomba; Miryoung Lee; Joseph B McCormick; Susan P Fisher-Hoch Journal: Hepatol Commun Date: 2020-10-31